{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:17:43Z","timestamp":1789449463579,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,3,4]],"date-time":"2017-03-04T00:00:00Z","timestamp":1488585600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s40266-017-0446-x","type":"journal-article","created":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T21:20:02Z","timestamp":1488576002000},"page":"303-310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Trends in the Prescription and Long-Term Utilization of Antidementia Drugs Among Patients with Alzheimer\u2019s Disease in Spain: A Cohort Study Using the Registry of Dementias of Girona"],"prefix":"10.1007","volume":"34","author":[{"name":"on behalf of the Registry of Dementias of Girona Study Group (ReDeGi Study Group)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Calv\u00f3-Perxas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Turr\u00f3-Garriga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Vilalta-Franch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Lozano-Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"de Eugenio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabi\u00e1n","family":"M\u00e1rquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Gich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Manzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Vi\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M\u00aa","family":"Roig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Garre-Olmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,4]]},"reference":[{"key":"446_CR1","doi-asserted-by":"crossref","unstructured":"Birks J. Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2006;(1):CD005593.","DOI":"10.1002\/14651858.CD005593"},{"key":"446_CR2","doi-asserted-by":"crossref","unstructured":"McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;(2):CD003154.","DOI":"10.1002\/14651858.CD003154.pub5"},{"key":"446_CR3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1532-5415.2008.02122.x","volume":"57","author":"FJ Molnar","year":"2009","unstructured":"Molnar FJ, Man-Son-Hing M, Fergusson D. Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia. J Am Geriatr Soc. 2009;57:536\u201346.","journal-title":"J Am Geriatr Soc."},{"key":"446_CR4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.7326\/0003-4819-148-5-200803040-00009","volume":"148","author":"P Raina","year":"2008","unstructured":"Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379\u201397.","journal-title":"Ann Intern Med."},{"key":"446_CR5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/alzrt7","volume":"1","author":"SD Rountree","year":"2009","unstructured":"Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS. Persistent treatment with cholinesterase inhibitors and\/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther. 2009;1:7.","journal-title":"Alzheimers Res Ther."},{"key":"446_CR6","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1474-4422(07)70195-3","volume":"6","author":"H Kavirajan","year":"2007","unstructured":"Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6:782\u201392.","journal-title":"Lancet Neurol."},{"key":"446_CR7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40263-013-0133-3","volume":"28","author":"V Gardette","year":"2014","unstructured":"Gardette V, Lapeyre-Mestre M, Piau A, Gallini A, Cantet C, Montastruc JL, Vellas B, Andrieu S, ICTUS Group. A 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer\u2019s disease in Europe: predictors of discontinuation and switch in the ICTUS study. CNS Drugs. 2014;28:157\u201370.","journal-title":"CNS Drugs."},{"key":"446_CR8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000347140","volume":"35","author":"R Brady","year":"2013","unstructured":"Brady R, Weinman J. Adherence to cholinesterase inhibitors in Alzheimer\u2019s disease: a review. Dement Geriatr Cogn Disord. 2013;35:351\u201363.","journal-title":"Dement Geriatr Cogn Disord."},{"key":"446_CR9","first-page":"383","volume":"10","author":"TH Lai","year":"2016","unstructured":"Lai TH, Wang WF, Yip BS, Yang YW, Peng GS, Tsai SJ, Liao YC, Pai MC. Real-world evaluation of compliance and preference in Alzheimer\u2019s disease treatment: an observational study in Taiwan. Patient Prefer Adherence. 2016;10:383\u201390.","journal-title":"Patient Prefer Adherence."},{"key":"446_CR10","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1017\/S1041610215000654","volume":"27","author":"J Bohlken","year":"2015","unstructured":"Bohlken J, Weber S, Rapp MA, Kostev K. Continuous treatment with antidementia drugs in Germany 2003\u20132013: a retrospective database analysis. Int Psychogeriatr. 2015;27:1335\u201342.","journal-title":"Int Psychogeriatr."},{"key":"446_CR11","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/YIC.0000000000000032","volume":"29","author":"H Taipale","year":"2014","unstructured":"Taipale H, Tanskanen A, Koponen M, et al. Antidementia drug use among community-dwelling individuals with Alzheimer\u2019s disease in Finland: a nationwide register-based study. Int Clin Psychopharmacol. 2014;29:216\u201323. doi: 10.1097\/YIC.0000000000000032 .","journal-title":"Int Clin Psychopharmacol"},{"key":"446_CR12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/WAD.0000000000000006","volume":"28","author":"B Haider","year":"2014","unstructured":"Haider B, Schmidt R, Schweiger C, Forstner T, Labek A, Lampl C. Medication adherence in patients with dementia: an Austrian cohort study. Alzheimer Dis Assoc Disord. 2014;28:128\u201333.","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"446_CR13","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/070674371405901203","volume":"59","author":"CJ Maxwell","year":"2014","unstructured":"Maxwell CJ, Stock K, Seitz D, Herrmann N. Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors. Can J Psychiatry. 2014;59:624\u201331.","journal-title":"Can J Psychiatry."},{"key":"446_CR14","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00228-013-1483-y","volume":"69","author":"L Brewer","year":"2013","unstructured":"Brewer L, Bennett K, McGreevy C, Williams D. A population-based study of dosing and persistence with anti-dementia medications. Eur J Clin Pharmacol. 2013;69:1467\u201375.","journal-title":"Eur J Clin Pharmacol."},{"key":"446_CR15","first-page":"1","volume":"50","author":"RR German","year":"2001","unstructured":"German RR, Armstrong G, Birkhead GS, Surveillance coordination Group. Updated guidelines for evaluating public health surveillance systems. MMWR Morb Mortal Wkly Rep. 2001;50:1\u201335.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"446_CR16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2377-9-5","volume":"9","author":"J Garre-Olmo","year":"2009","unstructured":"Garre-Olmo J, Flaqu\u00e9 M, Gich J, Pulido TO, Turbau J, Vallmajo N, Vi\u00f1as M, L\u00f3pez-Pousa S. A clinical registry of dementia based on the principle of epidemiological surveillance. BMC Neurol. 2009;9:5.","journal-title":"BMC Neurol."},{"key":"446_CR17","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412\u20134.","journal-title":"Neurology."},{"key":"446_CR18","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1192\/bjp.114.512.797","volume":"114","author":"G Blessed","year":"1968","unstructured":"Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral gray matter of elderly subjects. Br J Psychiatr. 1968;114:797\u2013811.","journal-title":"Br J Psychiatr."},{"key":"446_CR19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398.","journal-title":"J Psychiatr Res."},{"key":"446_CR20","unstructured":"Jiang J. Linear and generalized linear mixed models and their applications. Springer Series of Statistics. ISBN 978-0-387-47946-0; 2007."},{"key":"446_CR21","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3233\/JAD-160098","volume":"53","author":"J Garre-Olmo","year":"2016","unstructured":"Garre-Olmo J, Garcia-Ptacek S, Calv\u00f3-Perxas L, Turr\u00f3-Garriga O, L\u00f3pez-Pousa S, Eriksdotter M. Diagnosis of dementia in the specialist setting: a comparison between the Swedish Dementia Registry (SveDem) and the Registry of Dementias of Girona (ReDeGi). J Alzheimers Dis. 2016;53:1341\u201351.","journal-title":"J Alzheimers Dis."},{"key":"446_CR22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12913-015-0855-7","volume":"15","author":"M W\u00fcbbeler","year":"2015","unstructured":"W\u00fcbbeler M, Wucherer D, Hertel J, Michalowsky B, Heinrich S, Meyer S, Schaefer-Walkmann S, Hoffmann W, Thyrian JR. Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use. BMC Health Serv Res. 2015;15:205.","journal-title":"BMC Health Serv Res."},{"key":"446_CR23","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/jgs.14226","volume":"64","author":"D Koller","year":"2016","unstructured":"Koller D, Hua T, Bynum JP. Treatment patterns with antidementia drugs in the United States: medicare cohort study. J Am Geriatr Soc. 2016;64:1540\u20138.","journal-title":"J Am Geriatr Soc."},{"key":"446_CR24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/11591860-000000000-00000","volume":"28","author":"L Patel","year":"2011","unstructured":"Patel L, Grossberg GT. Combination therapy for Alzheimer\u2019s disease. Drugs Aging. 2011;28:539\u201346.","journal-title":"Drugs Aging."},{"key":"446_CR25","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12640-013-9398-z","volume":"24","author":"CG Parsons","year":"2013","unstructured":"Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer\u2019s disease. Neurotox Res. 2013;24:358\u201369.","journal-title":"Neurotox Res."},{"key":"446_CR26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13195-015-0109-2","volume":"7","author":"A Atri","year":"2015","unstructured":"Atri A, Hendrix SB, Pejovi\u0107 V, Hofbauer RK, Edwards J, Molinuevo JL, Graham SM. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer\u2019s dementia: a pooled area under the curve analysis. Alzheimers Res Ther. 2015;7:28.","journal-title":"Alzheimers Res Ther."},{"key":"446_CR27","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40266-016-0384-z","volume":"33","author":"C Parsons","year":"2016","unstructured":"Parsons C. Withdrawal of antidementia drugs in older people: who, when and how? Drugs Aging. 2016;33:545\u201356.","journal-title":"Drugs Aging."},{"key":"446_CR28","unstructured":"Development Group of the Clinical Practice Guideline on the comprehensive care of people with Alzheimer\u2019s disease and other dementias. Quality plan for the National Health System of the Ministry of Health, Social Policies and Equality. Ag\u00e8ncia d\u2019Informaci\u00f3, Avaluaci\u00f3 i Qualitat en Salut of Catalonia; 2010. Clinical Practice Guidelines in the Spanish National Health Service: AIAQS No. 2009\/07."},{"key":"446_CR29","first-page":"2016","volume-title":"Dementia: supporting people with dementia and their carers in health and social care","author":"National Institute for Health and Care Excellence","year":"2016","unstructured":"National Institute for Health and Care Excellence. Dementia: supporting people with dementia and their carers in health and social care. London: NICE; 2016. p. 2016."},{"key":"446_CR30","unstructured":"Societat Catalana de Neurologia. Grup d\u2019estudi de la cognici\u00f3 i la conducta. Guia diagn\u00f2stica i terap\u00e8utica de la malaltia d\u2019Alzheimer. 2015. http:\/\/www.scn.cat\/docs\/grups_treball\/2_Diagnostic_tractament_Alzheimer_2015.pdf . Accessed 25 Nov 2016."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-017-0446-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-017-0446-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-017-0446-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T07:52:43Z","timestamp":1498377163000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-017-0446-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["446"],"URL":"https:\/\/doi.org\/10.1007\/s40266-017-0446-x","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,4]]}}}